

Organized by



Supported By



An Initiative By



REVIEW

BEST OF SAN ANTONIO BREAST CANCER SYMPOSIUM

2022 VIRTUAL SUMMIT

Sunday, 6th MARCH 2022

14:00 - 16:00 Singapore Time

Chairperson: **NAN SOON WANG, SINGAPORE**

14:00 - 14:30

Satellite Symposium - Roche

Oral Selective Estrogen Receptor Degraders (SERDs): Emerging Treatment Option for HR +ve Breast Cancer

Chairperson: **YAP YOON SIM, SINGAPORE**

Speaker: **ELGENE LIM, AUSTRALIA**

14:30 - 14:45

Basic / Translational Science

Speaker: **ELGENE LIM, AUSTRALIA**

- **GS1-00:** Single-cell spatial analysis by imaging mass cytometry and immunotherapy response in triple-negative breast cancer (TNBC) in the NeoTRIPaPDL1 trial
- **GS1-10:** Clinical utility of molecular tumor profiling: Results from the randomized trial SAFIR02-BREAST
- **GS3-07:** Circulating tumor DNA (ctDNA) dynamics in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first line with ribociclib (R) and letrozole (L) in the BioItaLEE trial

14:45 - 15:05

Early Breast Cancer ER Positive HER2 Negative

Speaker: **VIRGINIA KAKLAMANI, USA**

- **GS2-04:** Aromatase inhibitors versus tamoxifen in pre-menopausal women with estrogen receptor positive early-stage breast cancer treated with ovarian suppression: A patient level meta-analysis of 7,030 women in four randomised trials
- **GS2-05:** Randomized comparison of adjuvant exemestane + OFS vs tamoxifen plus OFS in premenopausal women with HR+ early breast cancer: update of the combined TEXT and SOFT trials
- **GS2-07:** Updated results from a phase 3 randomized clinical trial in participants (pts) with 1-3 positive lymph nodes, hormone receptor-positive (HR+) and HER2-negative breast cancer with recurrence score of 25 or less: SWOG S1007

15:05 - 15:15

Early Breast Cancer Adjuvant/Neoadjuvant Therapy

Speaker: **TIRA TAN, SINGAPORE**

- **GS2-06:** Taxane with anthracycline versus taxane without anthracycline: An individual patient-level meta-analysis of 16,500 women with early-stage breast cancer in 13 randomised trials
- **GS1-02:** KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses

apbcs.org

Organized by



Supported By



An Initiative By



REVIEW

BEST OF SAN ANTONIO BREAST CANCER SYMPOSIUM

2022 VIRTUAL SUMMIT

Sunday, 6th MARCH 2022

14:00 - 16:00 Singapore Time

15:15 – 15:25

Local Therapy

Speakers: **VERONIQUE TAN, SINGAPORE | FAYE LIM, SINGAPORE**

- **GS4-05:** Preservation of axillary lymph nodes compared to complete dissection in T1-T2 breast cancer patients presenting 1-2 metastatic sentinel lymph nodes. A multicenter randomized clinical trial. Sinodar One

15:25 – 15:45

Advanced Breast Cancer ER Positive HER2 Negative

Speaker: **SHAHEENAH DAWOOD, UAE**

- **GS2-00:** Correlative analysis of overall survival by intrinsic subtype across the MONALEESA-2, -3, and -7 studies of ribociclib + endocrine therapy in patients with HR+/HER2- advanced breast cancer
- **GS3-05:** Results of PADA-1- Fulvestrant-palbociclib vs continuing AI-palbociclib upon detection of circulating ESR1 mutation in HR+ HER2 negative metastatic breast cancer
- **GS2-02:** Elacestrant, an oral SERD vs investigator's choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trial
- **GS3-010:** Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)

15:45 – 16:00

Advanced Breast Cancer Triple Negative/HER2 Positive/Immunotherapy

Speaker: **WONG NAN SOON, SINGAPORE**

- **GS3-01:** Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03
- **GS1-02:** Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer
- **GS2-10:** Nimbus: A phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated her2-negative metastatic breast cancer (MBC)
- **GS1-05:** Datopotamab deruxtecan in advanced/metastatic HER2- breast cancer: Results from the phase 1 TROPION-PanTumor01 study

apbcs.org